SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending after delivering another blowout earnings report with record revenue and strong guidance, showcasing robust demand driven by the AI boom. However, community discussions are rife with skepticism, questioning the stock's flat post-earnings price action, with many pointing to market manipulation and strategies to crush options.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is trending with high community excitement ahead of its annual results, driven by market anticipation of a significant share repurchase program and a potential dividend, alongside robust performance across its civil aviation, defense, and power generation segments.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is trending after its latest earnings report saw a beat on Q4 expectations, but its Q1 guidance fell short of analyst estimates, prompting a significant stock decline. Community discussions are heavily focused on CEO performance, substantial share price depreciation, and whether the company's strong fundamentals justify current market sentiment in the evolving ad-tech landscape.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with Knife ($CAW) is generating significant buzz as an organically grown, multi-chain meme coin praised by its community for a deflationary burning mechanism and broad integration across platforms like Base, Solana, and Cronos. Enthusiasts are actively calling it a "must-hold" with substantial future potential, encouraging others to "rotate" into the asset.

Memecoin on Injective taken over by the community.

Nonja

NONJA CRYPTO is trending as a key meme coin on the Injective ($INJ) blockchain, driven by community optimism over INJ's strengthening fundamentals, high developer activity, and potential deflationary tokenomics. The community highlights NONJA's strong resilience, high burned liquidity, and leveraged upside potential as the Injective ecosystem prepares for a significant market resurgence.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is surging following a blowout Q4 earnings report that exceeded expectations and provided strong guidance, with investors highlighting strategic acquisitions and significant government contract awards as catalysts for continued growth and potential short covering.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is trending after its nomlabofusp program, targeting the root cause of Friedreich's Ataxia, received FDA Breakthrough Therapy Designation based on strong open-label data; this milestone fuels optimism for an accelerated approval, though an upsized public offering has sparked investor debate on dilution versus critical funding for commercialization.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzle is trending following a robust Q4 earnings beat, raised FY2026 guidance, and a newly authorized $100 million stock repurchase program. The community is buzzing about the company's perceived undervaluation and the high potential for a short squeeze due to significant short interest and a tight share float.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is trending as investors digest its strong Q4 earnings and accelerated FAA certification progress, alongside the high-profile launch of Uber Air in Dubai, while community discussion balances excitement for its scaling and military partnerships against concerns over recent share dilution.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending after reporting mixed Q4 earnings, which included a revenue beat but a wider loss, alongside the announcement of its CEO's planned retirement. This has ignited community speculation about potential leadership changes and a buyout, further intensifying discussions around the company's perceived undervaluation despite Elevidys' international expansion and pipeline advancements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The patient had a tumor shrinkage of 50% and notable decline in the tumor biomarker CA-125, the company said.&nbsp;</li><li>The patient experienced only low-grade treatment-emergent adverse effects and continued treatment.</li><li>The company is now eyeing confirmation of the partial response observed in both its patients in subsequent imaging assessments.</li></ul>Shares of Aprea Therapeutics, Inc. (APRE) rallied 15% on Wednesday after the company said that it observed tumor shrinkage in a patient enrolled in an early-stage trial of its experimental drug APR-1051.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.aprea.com/news-releases/news-release-details/aprea-therapeutics-announces-additional-positive-clinical">reported</a> a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level. The patient had a tumor shrinkage of 50% and notable decline in the tumor biomarker CA-125, the company said.The patient experienced only low-grade treatment-emergent adverse effects and continued treatment, Aprea said. The first patient to achieve a partial response at 150 mg dose levels also remains on therapy as the experimental oral therapy is generally well-tolerated, the company added.<h2 class="st-heading-2">Steps Ahead</h2>The company is now eyeing confirmation of the partial response observed in both its patients in subsequent imaging assessments. Further updates from the trial are expected in the second quarter of 2026. The study is aimed at evaluating the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of APR-1051 in patients with advanced solid tumors and nearly 22 patients have been treated at varying doses of 10mg to 220 mg.“We believe the magnitude of tumor reduction and the substantial drop in CA-125 in this patient provides further evidence of APR-1051’s biologic activity and potential therapeutic impact,” said Eugene Kennedy, Chief Medical Advisor at Aprea.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around APRE stock increased from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume improved from ‘extremely low’ to ‘normal’ levels.According to data from Koyfin, all the three analysts covering the stock rate it ‘Buy’ or higher. The 12-month average price target on the stock is at $5.33, representing a potential upside of about 788% from last day’s closing price.<a href="https://stocktwits.com/symbol/APRE">APRE stock</a> has declined 80% over the past 12 months.&nbsp;Read More: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy">SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aprea Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial

The company reported a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level.

Equity

The company reported a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level.


Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars

Aprea Therapeutics shares rise after promising Phase 1 trial results with APR-1051 in cancer treatment.read more...

New Strong Sell Stocks for January 19th

APRE, NFE and CZR have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2026.

 New Strong Sell Stocks for Jan. 14

APRE, CULP and PSKY have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.

Marc Duey Acquires 21,459 Shares of Aprea Therapeutics (NASDAQ:APRE) Stock

Aprea Therapeutics, Inc. (NASDAQ:APRE - Get Free Report) Director Marc Duey purchased 21,459 shares of the firm's stock in a transaction on Wednesday, December 10th. The shares were acquired at an...

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.

Current Price	$0.875
Prev Close	$0.7999
Open	$0.78
Dividend Yield	0.00%
50-Day Moving Average	$0.822
Beta	0.71
Avg. Volume	5.84M
PE Ratio	-0.37

52-Week High	$2.79
52-Week Low	$0.548
Market Capitalization	$5.59M
EPS (Annual)	-$2.35
Price to Book	0.44
Revenue Per Employee	$187,822.63

APRE
Aprea Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest APRE News

APREAprea Therapeutics Inc